MOB

Moberg Pharma

Research update

Print

Moberg Pharma: No major drama in 3Q18

From our perspective, the outcome in 3Q18 was not that dramatic. The investment case is intact, with a growing profitable OTC business forming a base and a possible big up-side with MOB-015 (first top-line data 4Q19).

Continue reading (pdf) icon-download